Comorbid Depression And Anxiety: When And How To Treat ?

Q: Anxiety and depression are distinct disorders commonly seen in clinical practice, particularly in the primary care setting. Comorbid or mixed disorders are also encountered so frequently that a diagnostic category of "mixed anxiety-depressive disorder" appears in the appendix of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).

A:It is crucial for clinicians to recognize both anxiety and depression early in the clinical course and institute appropriate therapy aimed at making the patient well (ie, achieving full remission) rather than merely improving symptoms. Patients with comorbid anxiety and depression tend to discontinue treatment earlier than those with depression alone, and they may not respond as robustly to conventional treatments. Depression was once postulated to result from dysregulation of the noradrenergic system alone. Hence, the pathophysiology focused on levels of norepinephrine and noradrenergic dysfunction. With the introduction of the selective serotonin reuptake inhibitors (SSRIs), attention shifted to the role of serotonin in depression. The exact mechanisms underlying depression, however, are more complex than

is suggested simply by decreased levels of norepinephrine or serotonin. Benzodiazepines act by potentiating the effects of gamma-aminobutyric acid9 and have traditionally been the therapy of choice in anxiety disorders because they produce rapid relief of somatic symptoms. and they are at significantly increased risk of developing full-blown depression or anxiety. Appropriate treatment is necessary to alleviate symptoms and prevent the emergence of more serious disease. Accumulating evidence indicates that patients with comorbid depression and anxiety tend to have greater illness severity and a lower treatment response than those with either disorder alone.